J&J drug unit to leverage Singapore's biotech hub
'Very lively biotech hub' spurs pharmaceutical arm's external collaborations
Annabeth Leow
Singapore
JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.
Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".
TRENDING NOW
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
BlackRock said to be in exclusive due diligence for Capri by Fraser China Square
‘Very low chance’ that US-Iran deal reverts energy flows to South-east Asia through Hormuz: Bloomberg Economics
Tiger Beer lines up new products as Singapore operations’ role shifts from brewing to innovation